LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.
In this interview, Varner and Confer discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline.
“This work has become a real passion for me. We have the opportunity to do real good here at Genprex on a major scale – helping millions of people around the world with serious diseases through our novel gene therapies,” said Varner.
Confer then provided some background on what led him to join Genprex in its early days and remain with the company for well over a decade.
“As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.”
Varner and Confer also discuss the company’s cancer and diabetes treatments in greater detail.
“Our cancer treatment is distinguished from most other oncology gene therapies in that we’re using a tumor suppressor gene that is delivered to the tumor by a non-viral lipid nanoparticle,” said Varner. “The nanoparticles deliver the therapeutic DNA into the tumor, where our drug candidate does a number of things to reduce or eliminate the tumor.”
“We also have a really unique pre-clinical diabetes program. Unlike our oncology program, we use a viral delivery system with our diabetes program. However, we have a process in which we deliver genes directly to the pancreas using an endoscopic procedure to be able to localize the viral vector in that specific organ,” explained Confer.
Join IBN’s Stuart Smith and Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex Inc. (NASDAQ: GNPX), to learn more about the promise of gene therapy and Genprex’s development pipelines targeting oncology and diabetes. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 17 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company was founded in 2009 and is headquartered in Austin, Texas.
For more information, visit the company’s website at www.Genprex.com.
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and ssumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.